Aliases & Classifications for Peritoneum Cancer

MalaCards integrated aliases for Peritoneum Cancer:

Name: Peritoneum Cancer 12 15
Malignant Tumor of Peritoneum 73
Cancer of Peritoneum 12
Peritoneal Neoplasms 73
Peritoneal Neoplasm 12
Cancer, Peritoneal 40
Peritoneal Cancer 55

Classifications:



External Ids:

Disease Ontology 12 DOID:1725
ICD10 33 C48.1
ICD9CM 35 158.8
SNOMED-CT 68 187808008 187816004

Summaries for Peritoneum Cancer

Disease Ontology : 12 An organ system cancer that is located in the peritoneum.

MalaCards based summary : Peritoneum Cancer, also known as malignant tumor of peritoneum, is related to primary peritoneal carcinoma and peritoneal mesothelioma, and has symptoms including sister mary joseph's nodule An important gene associated with Peritoneum Cancer is BRCA2 (BRCA2, DNA Repair Associated), and among its related pathways/superpathways is Cytoskeletal Signaling. The drugs Dexamethasone and Antiemetics have been mentioned in the context of this disorder. Affiliated tissues include t cells, testes and ovary, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Peritoneum Cancer

Diseases related to Peritoneum Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Related Disease Score Top Affiliating Genes
1 primary peritoneal carcinoma 32.4 BRCA1 BRCA2
2 peritoneal mesothelioma 31.6 BAP1 WT1
3 fallopian tube carcinoma 30.1 BRCA1 BRCA2
4 pleural cancer 29.0 BAP1 KRT5 WT1
5 hereditary site-specific ovarian cancer syndrome 10.7 BRCA1 BRCA2
6 breast reconstruction 10.7 BRCA1 BRCA2
7 tuberculous salpingitis 10.7 BRCA1 BRCA2
8 nosophobia 10.7 BRCA1 BRCA2
9 cancerophobia 10.7 BRCA1 BRCA2
10 uterine corpus serous adenocarcinoma 10.7 BRCA1 BRCA2
11 breast-ovarian cancer, familial 1 10.7 BRCA1 BRCA2
12 synchronous bilateral breast carcinoma 10.6 BRCA1 BRCA2
13 fallopian tube adenocarcinoma 10.6 BRCA1 BRCA2
14 glycogen-rich clear cell breast carcinoma 10.6 BRCA1 BRCA2
15 premature menopause 10.6 BRCA1 BRCA2
16 clear cell adenofibroma 10.6 BRCA1 BRCA2
17 bap1 tumor predisposition syndrome 10.6 BAP1 BRCA2
18 ocular melanoma 10.5 BAP1 BRCA2
19 lynch syndrome i 10.5 BRCA1 BRCA2
20 bilateral breast cancer 10.5 BRCA1 BRCA2
21 tumor predisposition syndrome 10.5 BAP1 BRCA2
22 mutagen sensitivity 10.5 BRCA1 BRCA2
23 odontoma 10.4 KRT5 TUBB3
24 breast giant fibroadenoma 10.4 BRCA2 WT1
25 female reproductive organ cancer 10.3 BRCA1 BRCA2 TUBB3
26 papillary serous adenocarcinoma 10.3 BRCA1 PTGER4
27 peritonitis 10.2
28 cystadenofibroma 10.2 BRCA1 BRCA2 KRT5
29 pre-malignant neoplasm 10.2 BRCA1 BRCA2 KRT5
30 malignant biphasic mesothelioma 10.2 KRT5 WT1
31 breast carcinoma in situ 10.2 BRCA1 BRCA2 KRT5
32 ductal carcinoma in situ 10.2 BRCA1 BRCA2 KRT5
33 large cell acanthoma 10.1 KRT5 PTGER4
34 dysgerminoma of ovary 10.1 BRCA1 BRCA2 WT1
35 female breast cancer 10.1 BRCA1 BRCA2
36 peritoneal serous papillary adenocarcinoma 10.1 PTGER4 WT1
37 malignant epithelial mesothelioma 10.1 PTGER4 WT1
38 peritoneal serous adenocarcinoma 10.1 PTGER4 WT1
39 benign mesothelioma 10.0 KRT5 WT1
40 in situ carcinoma 10.0 BRCA1 KRT5
41 combined thymoma 9.9 KRT5 PAX8
42 sebaceous adenocarcinoma 9.9 KRT5 PTGER4
43 ovarian cancer 9.9
44 ocular cancer 9.7 BAP1 BRCA2
45 urethral diverticulum 9.7 PAX8 WT1
46 lynch syndrome 9.7
47 rete testis neoplasm 9.6 PAX8 PTGER4
48 nephrogenic adenofibroma 9.6 PAX8 WT1
49 wernicke-korsakoff syndrome 9.5
50 gastric cancer 9.5

Comorbidity relations with Peritoneum Cancer via Phenotypic Disease Network (PDN):


Ovarian Cancer

Graphical network of the top 20 diseases related to Peritoneum Cancer:



Diseases related to Peritoneum Cancer

Symptoms & Phenotypes for Peritoneum Cancer

UMLS symptoms related to Peritoneum Cancer:


sister mary joseph's nodule

GenomeRNAi Phenotypes related to Peritoneum Cancer according to GeneCards Suite gene sharing:

26 (show all 43)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.35 WT1 ITPR3
2 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.35 ITPR3
3 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.35 BRCA1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.35 WT1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.35 ITPR3
6 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.35 PDE4DIP
7 Increased shRNA abundance (Z-score > 2) GR00366-A-129 10.35 PDE4DIP
8 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.35 PDE4DIP
9 Increased shRNA abundance (Z-score > 2) GR00366-A-135 10.35 BRCA1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.35 ITPR3 BRCA1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.35 ITPR3
12 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.35 WT1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.35 PDE4DIP
14 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.35 ITPR3
15 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.35 PAX8
16 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.35 BRCA1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.35 ITPR3 PDE4DIP
18 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.35 ITPR3
19 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.35 BRCA1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.35 ITPR3
21 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.35 ITPR3
22 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.35 ITPR3
23 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.35 ITPR3
24 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.35 ITPR3
25 Increased shRNA abundance (Z-score > 2) GR00366-A-208 10.35 ITPR3
26 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.35 WT1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.35 WT1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.35 PAX8
29 Increased shRNA abundance (Z-score > 2) GR00366-A-3 10.35 PAX8
30 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.35 WT1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.35 WT1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10.35 PDE4DIP
33 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.35 PAX8
34 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.35 ITPR3 WT1 PAX8 BRCA1 PDE4DIP
35 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.35 WT1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.35 BRCA1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-56 10.35 ITPR3
38 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.35 BRCA1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-76 10.35 ITPR3
40 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.35 ITPR3 PAX8
41 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.35 WT1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.35 PAX8
43 Synthetic lethal with cisplatin GR00101-A-1 8.62 BRCA1 BRCA2

MGI Mouse Phenotypes related to Peritoneum Cancer:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 10.1 BRCA1 KRT5 BRCA2 PAX8 BAP1 ITPR3
2 behavior/neurological MP:0005386 10.08 ITPR3 BRCA1 KRT5 BRCA2 PDE4DIP PTGER4
3 growth/size/body region MP:0005378 10.08 BRCA1 KRT5 BRCA2 PAX8 BAP1 ITPR3
4 cellular MP:0005384 10.07 BRCA1 BRCA2 BAP1 PAX8 PTGER4 TUBB3
5 endocrine/exocrine gland MP:0005379 9.97 ITPR3 BRCA1 BRCA2 BAP1 WT1 PAX8
6 integument MP:0010771 9.93 BRCA1 KRT5 BRCA2 BAP1 ITPR3 PTGER4
7 digestive/alimentary MP:0005381 9.91 ITPR3 BRCA1 KRT5 BRCA2 BAP1
8 limbs/digits/tail MP:0005371 9.83 ITPR3 BRCA1 KRT5 PAX8 BRCA2
9 muscle MP:0005369 9.77 BAP1 ITPR3 BRCA1 PTGER4 WT1
10 neoplasm MP:0002006 9.72 BRCA1 BRCA2 BAP1 PTGER4 WT1
11 no phenotypic analysis MP:0003012 9.65 ITPR3 KRT5 BAP1 WT1 PAX8
12 normal MP:0002873 9.63 ITPR3 BRCA1 BRCA2 PTGER4 WT1 PAX8
13 reproductive system MP:0005389 9.43 ITPR3 BRCA1 BRCA2 BAP1 WT1 PAX8
14 respiratory system MP:0005388 9.02 BRCA1 BAP1 PTGER4 TUBB3 WT1

Drugs & Therapeutics for Peritoneum Cancer

Drugs for Peritoneum Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 375)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
2 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
4 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
8 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16
Carboplatin Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
17
Ifosfamide Approved Phase 2, Phase 3,Phase 3 3778-73-2 3690
18
Mechlorethamine Approved, Investigational Phase 2, Phase 3,Phase 3 51-75-2 4033
19
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
20
Cisplatin Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
21
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
22
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
23
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
24
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
25
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
26
Tamoxifen Approved Phase 3,Phase 2,Phase 1 10540-29-1 2733526
27
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
28
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
29
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 61825-94-3 5310940 9887054 43805 6857599
30
Olaparib Approved Phase 3,Phase 2,Phase 1 763113-22-0 23725625
31
Epirubicin Approved Phase 3 56420-45-2 41867
32
Alvimopan Approved, Investigational Phase 3 156053-89-3 5488548
33
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
34
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
35
Trastuzumab Approved, Investigational Phase 3,Phase 1 180288-69-1 9903
36
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1 97682-44-5, 100286-90-6 60838
37
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
38
Rucaparib Approved, Investigational Phase 3,Phase 2,Phase 1 283173-50-2 9931954
39
Bupivacaine Approved, Investigational Phase 3 2180-92-9, 38396-39-3 2474
40
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
41
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
42
Adenosine Approved, Investigational Phase 3 58-61-7 60961
43
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 77-92-9 311
44
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
45
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
46
Pyridoxal Approved, Nutraceutical Phase 3 66-72-8 1050
47
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
48
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 2,Early Phase 1 56-86-0 33032
49
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
50
Cediranib Investigational Phase 3,Phase 2,Phase 1 288383-20-0 9933475

Interventional clinical trials:

(show top 50) (show all 683)
# Name Status NCT ID Phase Drugs
1 Tumor Gene Expression in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
2 Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy Unknown status NCT00004115 Phase 3
3 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
4 Dexamethasone Regimens for Prophylaxis of Paclitaxel-associated Hypersensitivity Reaction Unknown status NCT02349763 Phase 3 Intravenous Dexamethasone;Oral Dexamethasone
5 ICON8: Weekly Chemotherapy in Ovarian Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
6 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
7 Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer Unknown status NCT01091636 Phase 2, Phase 3
8 An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
9 Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00098878 Phase 3 carboplatin
10 Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00866697 Phase 3 Pazopanib;Placebo
11 Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer Completed NCT00262990 Phase 3 EPO906 (Patupilone);doxorubicin
12 Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00002895 Phase 3 chemotherapy
13 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
14 A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. Completed NCT00191607 Phase 3 Gemcitabine;liposomal doxorubicin
15 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
16 Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Completed NCT00004934 Phase 3 carboplatin;epirubicin hydrochloride;paclitaxel
17 Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Completed NCT00075712 Phase 2, Phase 3 carboplatin;paclitaxel
18 Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT00263822 Phase 3 erlotinib hydrochloride
19 S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Completed NCT00003120 Phase 3 paclitaxel
20 Comparison of Combination Chemotherapy Regimens in Treating Newly Diagnosed Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT00028743 Phase 3 carboplatin;cisplatin;paclitaxel;topotecan hydrochloride
21 TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer Completed NCT01204749 Phase 3 AMG 386;AMG 386 Placebo;Paclitaxel;Paclitaxel
22 Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00041080 Phase 3 tamoxifen citrate;thalidomide
23 Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer Completed NCT02311907 Phase 3 Carboplatin;Glutathione;Paclitaxel
24 S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer Completed NCT00043082 Phase 3 carboplatin;pegylated liposomal doxorubicin hydrochloride
25 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer Completed NCT00011986 Phase 3 Paclitaxel;Carboplatin;Gemcitabine Hydrochloride;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
26 Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer Completed NCT01196741 Phase 2, Phase 3 Paclitaxel;Saracatinib;Matched placebo
27 Study of Paclitaxel in Patients With Ovarian Cancer Completed NCT00989131 Phase 3 Paclical®;Taxol®
28 AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer Completed NCT00976911 Phase 3 bevacizumab [Avastin];liposomal doxorubicin;paclitaxel;topotecan
29 Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer Completed NCT00002894 Phase 3 carboplatin;cisplatin;paclitaxel
30 Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003636 Phase 3 carboplatin;cisplatin
31 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
32 OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer Completed NCT00382811 Phase 3 phenoxodiol;carboplatin;placebo
33 Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer Completed NCT00003998 Phase 3 carboplatin;docetaxel;paclitaxel
34 An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy Completed NCT00191646 Phase 3 Gemcitabine;Paclitaxel;Carboplatin
35 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
36 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer Completed NCT00245050 Phase 3 Placebo;doxorubicin HCL liposome
37 Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer Completed NCT00769405 Phase 3 fluorouracil;leucovorin calcium;oxaliplatin
38 Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane Completed NCT02728622 Phase 3 Tamoxifen;Chemotherapy
39 Accelerating Gastrointestinal Recovery Completed NCT01704651 Phase 3 Alvimopan;Placebo
40 TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer Completed NCT00102973 Phase 3 TLK286 in Combination with Carboplatin;Doxorubicin HCl Liposome Injection
41 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
42 A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma Completed NCT00434642 Phase 3 Carboplatin;Gemcitabine;Bevacizumab;Placebo
43 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
44 ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Recruiting NCT02855944 Phase 3 Chemotherapy;Rucaparib
45 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
46 Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
47 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT03038100 Phase 3 Paclitaxel;Carboplatin;Atezolizumab;Bevacizumab;Atezolizumab Placebo
48 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
49 Platine, Avastin and OLAparib in 1st Line Recruiting NCT02477644 Phase 3 Olaparib;Placebo
50 Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epidermal Analgesia (TEA) in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) on an Enhanced Rec Recruiting NCT03359811 Phase 3 Local Anesthetic Solution;Bupivacaine HCl;Liposomal Bupivacaine

Search NIH Clinical Center for Peritoneum Cancer

Genetic Tests for Peritoneum Cancer

Anatomical Context for Peritoneum Cancer

MalaCards organs/tissues related to Peritoneum Cancer:

41
T Cells, Testes, Ovary, Colon, Bone, Appendix, Breast

Publications for Peritoneum Cancer

Articles related to Peritoneum Cancer:

# Title Authors Year
1
Pattern of retroperitoneal dissemination of primary peritoneum cancer: basis for rational use of lymphadenectomy. ( 19361840 )
2009

Variations for Peritoneum Cancer

Expression for Peritoneum Cancer

Search GEO for disease gene expression data for Peritoneum Cancer.

Pathways for Peritoneum Cancer

Pathways related to Peritoneum Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.29 BAP1 KRT5 TUBB3

GO Terms for Peritoneum Cancer

Cellular components related to Peritoneum Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.61 BAP1 BRCA1 BRCA2 ITPR3 KRT5 PAX8
2 lateral element GO:0000800 8.62 BRCA1 BRCA2

Biological processes related to Peritoneum Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.71 BRCA1 BRCA2 PAX8 WT1
2 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.48 BRCA1 BRCA2
3 branching involved in ureteric bud morphogenesis GO:0001658 9.46 PAX8 WT1
4 DNA synthesis involved in DNA repair GO:0000731 9.43 BRCA1 BRCA2
5 strand displacement GO:0000732 9.37 BRCA1 BRCA2
6 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.32 BRCA1 BRCA2
7 cellular response to gonadotropin stimulus GO:0071371 9.26 PAX8 WT1
8 metanephric S-shaped body morphogenesis GO:0072284 9.16 PAX8 WT1
9 metanephric epithelium development GO:0072207 8.96 PAX8 WT1
10 chordate embryonic development GO:0043009 8.62 BRCA1 BRCA2

Molecular functions related to Peritoneum Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.65 BAP1 BRCA1 BRCA2 ITPR3 KRT5 PAX8
2 transcription regulatory region DNA binding GO:0044212 8.8 BRCA1 PAX8 WT1

Sources for Peritoneum Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....